Quantcast
Home > Quotes > SLS
SLS

SELLAS Life Sciences Group, Inc. Common Stock (SLS) Quote & Summary Data

$0.139
*  
0.002
1.42%
Get SLS Alerts
*Delayed - data as of Jul. 17, 2019  -  Find a broker to begin trading SLS now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    SLS After Hours
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 0.1389 / $ 0.1398
1 Year Target
8.75
Today's High / Low
$ 0.1479 / $ 0.137
Share Volume
31,169,986
50 Day Avg. Daily Volume
18,868,775
Previous Close
$ 0.141
52 Week High / Low
$ 2.46 / $ 0.1021
Market Cap
17,749,038
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
1.02

Intraday Chart

Shares Traded

Share Volume:
31,169,986
50 Day Avg. Daily Volume:
18,868,775

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -2.42

Trading Range

The current last sale of $0.139 is 36.14% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 0.1479 $ 2.46
 Low: $ 0.137 $ 0.1021

Company Description (as filed with the SEC)

We are a clinical-stage biopharmaceutical company focused on developing novel cancer immunotherapeutics for a broad range of cancer indications. Our product candidates currently include galinpepimut-S and nelipepimut-S. Galinpepimut-S, or GPS Our lead product candidate, galinpepimut-S, or GPS, is a cancer immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. In November 2018, following discussions with the U.S.  ... More ...  



Risk Grade

Where does SLS fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 0.1438
Open Date:
Jul. 17, 2019
Close Price:
$ 0.139
Close Date:
Jul. 17, 2019


Consensus Recommendation

Analyst Info